As for the potential clinical impact of a priori discovery of drug–resistance mutations to novel cancer drugs, our previous experience with the ABL kinase inhibitor dasatinib in chronic myeloid leukemia serves as an example. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.